#SME #StarImagin #StarImagingandPathLab
Star Imaging and Path Lab Limited H2FY26 Concall Highlights
👉 FY27 & Future Outlook
▫️Management reiterated 25-30% YoY revenue growth guidance for FY27
💠Expects this momentum to remain consistent over the next 2–3 years.
💠Key drivers include new center ramp-ups, B2C expansion, B2B hospital tie-ups, and operating leverage on a stable cost base.
▫️EBITDA margins expected to stay sustainable around 37.5%
💠PAT margins likely to remain healthy in the 21–22% range.
▫️Capex guidance for FY27: ₹20–25 crores, primarily for new centers, equipment, and upgrades.
💠Dwarka center (major B2C project) already opened; expected to contribute meaningfully from H1 FY27.
👉 Current Projects, Expansions & Pipeline
▫️Dwarka B2C Center:
💠New flagship center with ~₹14 crores capex.
💠Expected initial annual revenue ₹5–6 crores, blended EBITDA margins 35–40%.
💠Break-even targeted in 6–12 months (12 months for this larger center); project payback 2.5–3 years.
💠Response so far described as encouraging though still in early gestation.
▫️Existing Center Upgrades:
💠Vikaspuri center expanded and upgraded with new MRI and CT machines (already operational).
💠Tilak Nagar center upgraded with 640-slice CT scan.
▫️B2B / Hospital Tie-ups: Network significantly expanded to 100 hospitals (added 40–45 new empanelments during the year).
💠Tied up with RG Hospital (CT machine installed and commercialized).
💠4 additional tie-ups with RG Stone in pipeline (smaller capex ~₹2 crores each, faster break-even expected).
▫️B2G: Empaneled with Central Government Health Scheme (CGHS) – provides revenue stability.
💠Regulatory challenges caused delays in past projects; management confident these are now largely addressed, with two new centers already operational and more coming online soon.
▫️Pipeline remains healthy with additional B2C and B2B projects in various stages; focus remains on B2C as primary growth lever (B2G tender-dependent, B2B complementary).
👉 Other Notable Points
▫️Balance Sheet & Working Capital:
💠Trade receivables stood at ₹49.9 crores (elevated due to B2G payment cycles of ~6 months).
💠Net cash position ₹31.0 crores; total debt ₹20.6 crores.
💠Management actively working on faster collections and expects further normalization.
💠 Aim to remain largely debt-free, though selective borrowing possible for large tender opportunities.
▫️Business Mix (FY26): Radiology ~83%, Pathology ~14%. Multi-channel model – B2C 18%, B2B 10%, B2G stable. 24 diagnostic centers, team of 236, 7.1 lakh tests conducted.
▫️AI Impact:
💠Currently nascent in radiology (helps with preliminary reporting on X-rays/CTs) but requires radiologist sign-off.
💠No material disruption expected; viewed as productivity enhancer rather than replacement.
▫️Competition & Strategy:
💠Company continues to compete effectively with larger players (e.g., Dr Lal PathLabs is primarily pathology-focused).
💠Emphasis on latest technology, quality accreditations (NABL, NABH), brand strength, and strategic location selection.
👉Mainboard stocks often get all the attention but some of the most compelling businesses are hiding in plain sight — on the SME Platform.
👉Smaller. Less covered, though noisy at times. Yet occasionally, genuinely exceptional.
———
👉Introducing SME Gems — a new independent series on Hidden Champions of the SME Platform :
💠 OBSC Perfection
💠 Aimtron Electronics
💠 Yash Highvoltage
💠 CFF Fluid Control
💠 DSM Fresh Foods
💠 L.T. Elevator
💠 Monolithisch India
💠 GSM Foils
👉Across Different Sectors. One common place.
🔗
smeresearch.github.io/SMEGem…
👉Stay tuned for more insights
———
⚠️ For educational purposes only. Not investment advice. Please DYODD.
#SMEGems #SMEPlatform #HiddenChampions #SME